OCULAR THERAPEUTIX
Live / Allowed — Notice of allowance issued (as of 17 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 30 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99259760
- Mark type
- Design + words
- Filed
- 30 Jun 2025
- Published for opposition
- 20 Jan 2026
- Attorney of record
- Matthew P. Hintz, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of ophthalmic diseases and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of glaucoma, dry eye disease, macular degeneration, and lowering intraocular pressure, namely, ophthalmic pharmaceutical preparations that are delivered using implantable intravitreal drug delivery devices that are filled and sold with ophthalmic pharmaceutical preparations; Pharmaceutical preparations for the treatment of glaucoma, dry eye disease, and macular degeneration; Pharmaceutical preparations for the treatment of lowering intraocular pressure; Pharmaceutical preparations for the treatment of eye diseases and conditions, namely, dexamethasone that is delivered using implantable intravitreal drug delivery devices that are filled and sold with dexamethasone; Pharmaceutical preparations for the treatment of post-op pain and inflammation of the eye, and itching associated with allergic conjunctivitis, namely dexamethasone that is delivered using implantable intravitreal drug delivery devices that are filled and sold with dexamethasone; Ophthalmic preparations
- Class 042 — Scientific and technological services: Research and development in the field of pharmaceuticals and biopharmaceuticals; Product development in the field of pharmaceutical and biopharmaceutical preparations, inserts being implantable intravitreal drug delivery devices, implants, and medicines; Development of pharmaceutical preparations and medicines; Product development in the field of pharmaceuticals and biopharmaceuticals
Owner
- OCULAR THERAPEUTIX, INC., Bedford, MA, US
- OCULAR THERAPEUTIX, INC., Bedford, MA, US
Prosecution history
- 17 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 20 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 Jan 2026 — PUBLISHED FOR OPPOSITION
- 14 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 18 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 17 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 17 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 18 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 18 Nov 2025 — NON-FINAL ACTION E-MAILED
- 18 Nov 2025 — NON-FINAL ACTION WRITTEN
- 18 Nov 2025 — ASSIGNED TO EXAMINER
- 07 Nov 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 07 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 30 Jun 2025 — APPLICATION FILING RECEIPT MAILED